Evidence map›Paper›PMID 34767437›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Taking a BiTE Out of CAR-T Cell Efficacy.

Haley M Newman, David T Teachey

Abstract readEditorialComment
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Haley M NewmanThe Children's Hospital of Philadelphia, Philadelphia, PA.ORCID 0000-0002-3022-8052
David T TeacheyThe Children's Hospital of Philadelphia, Philadelphia, PA.ORCID 0000-0001-7373-8987

Funding

CANCER RESEARCH TRAINING PROGRAMT32CA009615 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Gregory L Beatty, MICHAEL D HOGARTY · 1988 to 2026
$10.4M
Improving risk allocation and developing novel therapies for children with T-ALL and T-LLR01CA193776 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI Terzah M Horton, ADAM B OLSHEN · 2015 to 2026
$6.2M
COG NCTN Integrated Translational Science Center for Hematopoietic Malignancies in ChildrenUG1CA233249 · NCI · PUBLIC HEALTH INSTITUTE · PI MESHINCHI, SOHEIL · 2019 to 2025
$4.9M
Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemiaR01CA264837 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI TEACHEY, DAVID T., YANG, JUN J. · 2021 to 2025
$3.0M
Genomic Profiling of T-cell Acute Lymphoblastic Leukemia in ChildrenR03CA256550 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MULLIGHAN, CHARLES G., TEACHEY, DAVID T. · 2021 to 2021
$382k
NCI NIH HHS R01 CA193776NCI NIH HHS R01 CA264837NCI NIH HHS R03 CA256550NCI NIH HHS T32 CA009615NCI NIH HHS UG1 CA233249
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Receptors, Chimeric AntigenHumansImmunotherapy, AdoptiveT-LymphocytesReceptors, Chimeric Antigen

Identifiers

PMID34767437
PMCPMC8937006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.